Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences Q4 EPS $(1.13) Misses $(0.87) Estimate, Sales $515.03K Beat $390.00K Estimate
Ensysce Biosciences第四季度每股收益美元（1.13）未达到预期（0.87），销售额为515.03万美元，超过预期的390.00万美元
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of $(18.24) per share from the same period last year. The company reported quarterly sales of $515.03 thousand which beat the analyst consensus estimate of $390.00 thousand by 32.06 percent. This is a 64.06 percent decrease over sales of $1.43 million the same period last year.
Ensysce Biosciences（纳斯达克股票代码：ENSC）公布的季度亏损为每股1.13美元，比分析师普遍预期的0.87美元（0.87美元）低29.89％。这比去年同期每股亏损18.24美元（18.24美元）增长了93.8％。该公司公布的季度销售额为515,030美元，比分析师普遍预期的39万美元高出32.06％。这比去年同期的143万美元销售额下降了64.06％。